AMH protects the ovary from doxorubicin by regulating cell fate and the response to DNA damage

we aim to explore the single-cell mechanisms behind ovarian damage in prepubertal mice following doxorubicin (DOX) treatment, and how Anti-Müllerian hormone (AMH) prevents chemotherapy-induced pathological damage, using single-cell RNA sequencing as well as quantitative and morphometric histological evaluation. Overall design: we treated mice (n=5) at the prepubertal age (postnatal day 25) with two weekly doses of DOX (3mg/kg). Additionally, we co-treated another group of mice with recombinant human AMH (rhAMH) (0.75mg/kg), the dose that was proven previously to protect the ovarian reserve to assess the protective effects of AMH. For comparison, we also included a group that received only rhAMH treatment. Ovaries were collected 4 hours after the second dose of DOX.